PZRXQ (PhaseRx) Total Current Liabilities: $2.73 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx Total Current Liabilities?

PhaseRx PZRXQ -99.00% Total Current Liabilities is $2.73 Mil as of Sep. 2017.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. PhaseRx's total current liabilities for the quarter that ended in Sep. 2017 was $2.73

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

PhaseRx Total Current Liabilities Related Terms

PhaseRx Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for PhaseRx's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx Total Current Liabilities Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Total Current Liabilities
15.80 23.93 2.02

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 2.02 2.73 2.84 2.73

PhaseRx Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

PhaseRx's Total Current Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.767+0.576
+Other Current Liabilities+Current Deferred Liabilities
=0.681+0
=2.02

PhaseRx's Total Current Liabilities for the quarter that ended in Sep. 2017 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.898+1.83
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $2.73 Mil mean?
PhaseRx (PZRXQ) has a Total Current Liabilities of $2.73 Mil as of Sep. 2017. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors.
Is PhaseRx's Total Current Liabilities too high?
PhaseRx's current Total Current Liabilities is $2.73 Mil.
How does PhaseRx's Total Current Liabilities compare to NSPX and HSTC?
PhaseRx's Total Current Liabilities of $2.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors. PhaseRx's current Total Current Liabilities is $2.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current Total Current Liabilities of $2.73 Mil. The current Total Current Liabilities is $2.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current Total Current Liabilities is $2.73 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.